Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update

Abstract

Get full access to this article

View all access options for this article.

References

Lebwohl

MG.

Papp

KA.

Marangell

et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81-89.doi:10.1016/j.jaad.2017.08.024

Foulkes

AC.

Warren

. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.doi:10.7573/dic.212570

Cohen

BE.

Martires

KJ.

. Psoriasis and the risk of depression in the US population: National health and nutrition examination survey 2009-2012. JAMA Dermatol. 2016;152(1):73-79.doi:10.1001/jamadermatol.2015.3605

Dalgard

FJ.

Gieler

Tomas-Aragones

et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991.doi:10.1038/jid.2014.530

Kurd

SK.

Troxel

AB.

Crits-Christoph

Gelfand

. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895.doi:10.1001/archdermatol.2010.186

Gooderham

Gavino-Velasco

Clifford

et al. A review of psoriasis, therapies, and suicide. J Cutan Med Surg. 2016;20(4):293-303.doi:10.1177/1203475416648323

SILIQTM Product Monograph. Bausch Health, Canada Inc. June 7, 2019

Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update—Author Response

Abstract

Get full access to this article

References